Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free NNNN Stock Alerts

Anbio Biotechnology (NNNN) Competitors

Anbio Biotechnology logo
$26.94 +1.87 (+7.46%)
Closing price 04:00 PM Eastern
Extended Trading
$26.25 -0.69 (-2.56%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NNNN vs. RGC, BBIO, AXSM, ARWR, and ELAN

Should you buy Anbio Biotechnology stock or one of its competitors? MarketBeat compares Anbio Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anbio Biotechnology include Regencell Bioscience (RGC), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Anbio Biotechnology compare to Regencell Bioscience?

Anbio Biotechnology (NASDAQ:NNNN) and Regencell Bioscience (NASDAQ:RGC) are both manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Regencell Bioscience had 21 more articles in the media than Anbio Biotechnology. MarketBeat recorded 22 mentions for Regencell Bioscience and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Regencell Bioscience's score of 0.04 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company Overall Sentiment
Anbio Biotechnology Positive
Regencell Bioscience Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Anbio Biotechnology has higher revenue and earnings than Regencell Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anbio Biotechnology$8.65M448.14$6.40MN/AN/A
Regencell BioscienceN/AN/A-$3.58MN/AN/A

Anbio Biotechnology has a beta of 4.71, suggesting that its share price is 371% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Anbio BiotechnologyN/A N/A N/A
Regencell Bioscience N/A N/A N/A

Summary

Anbio Biotechnology beats Regencell Bioscience on 5 of the 8 factors compared between the two stocks.

How does Anbio Biotechnology compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

In the previous week, BridgeBio Pharma had 32 more articles in the media than Anbio Biotechnology. MarketBeat recorded 33 mentions for BridgeBio Pharma and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat BridgeBio Pharma's score of 0.64 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
BridgeBio Pharma Positive
Anbio Biotechnology Positive

BridgeBio Pharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, suggesting that its stock price is 371% more volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-124.42% N/A -65.81%
Anbio Biotechnology N/A N/A N/A

BridgeBio Pharma currently has a consensus target price of $88.19, indicating a potential upside of 33.36%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
1 Sell rating(s)
0 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.92
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has lower revenue, but higher earnings than BridgeBio Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$502.08M25.80-$724.93M-$3.74N/A
Anbio Biotechnology$8.65M448.14$6.40MN/AN/A

Summary

BridgeBio Pharma beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Anbio Biotechnology has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Anbio Biotechnology's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-26.59% -267.16% -28.53%
Anbio Biotechnology N/A N/A N/A

Axsome Therapeutics presently has a consensus price target of $251.26, indicating a potential upside of 10.34%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
2.90
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Axsome Therapeutics had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for Axsome Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Axsome Therapeutics' score of 0.72 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Axsome Therapeutics Positive
Anbio Biotechnology Positive

Axsome Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its share price is 371% more volatile than the broader market.

Anbio Biotechnology has lower revenue, but higher earnings than Axsome Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M18.35-$183.17M-$3.73N/A
Anbio Biotechnology$8.65M448.14$6.40MN/AN/A

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Axsome Therapeutics beats Anbio Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Anbio Biotechnology has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$829.45M13.02-$1.63M-$2.15N/A
Anbio Biotechnology$8.65M448.14$6.40MN/AN/A

In the previous week, Arrowhead Pharmaceuticals had 27 more articles in the media than Anbio Biotechnology. MarketBeat recorded 28 mentions for Arrowhead Pharmaceuticals and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Arrowhead Pharmaceuticals' score of 0.48 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Arrowhead Pharmaceuticals Neutral
Anbio Biotechnology Positive

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its share price is 371% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus price target of $87.80, suggesting a potential upside of 14.52%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Anbio Biotechnology has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Anbio Biotechnology's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-48.38% -55.09% -18.13%
Anbio Biotechnology N/A N/A N/A

Summary

Arrowhead Pharmaceuticals beats Anbio Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Anbio Biotechnology compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Anbio Biotechnology has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Anbio Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Elanco Animal Health-4.95% 7.42% 3.66%
Anbio Biotechnology N/A N/A N/A

In the previous week, Elanco Animal Health had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for Elanco Animal Health and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.49 beat Elanco Animal Health's score of 0.14 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company Overall Sentiment
Elanco Animal Health Neutral
Anbio Biotechnology Positive

Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its stock price is 371% more volatile than the broader market.

Anbio Biotechnology has lower revenue, but higher earnings than Elanco Animal Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$4.72B2.10-$232M-$0.50N/A
Anbio Biotechnology$8.65M448.14$6.40MN/AN/A

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Elanco Animal Health presently has a consensus price target of $28.20, indicating a potential upside of 42.04%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, equities analysts clearly believe Elanco Animal Health is more favorable than Anbio Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
Anbio Biotechnology
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Elanco Animal Health beats Anbio Biotechnology on 10 of the 15 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for NNNN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NNNN vs. The Competition

Export
MetricAnbio BiotechnologyIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ Exchange
Market Cap$3.61B$962.42M$4.22B$12.47B
Dividend YieldN/AN/A5.92%5.28%
P/E RatioN/AN/A22.9225.25
Price / Sales448.14249.62162.7377.44
Price / Cash563.30563.3050.1456.01
Price / Book128.2964.5638.266.91
Net Income$6.40M-$18.48M$113.55M$333.88M
7 Day Performance4.26%8.00%2.60%0.01%
1 Month Performance-2.04%24.30%4.57%1.75%
1 Year PerformanceN/A-62.91%16.53%32.67%

Anbio Biotechnology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NNNN
Anbio Biotechnology
1.3205 of 5 stars		$26.94
+7.5%		N/AN/A$3.61B$8.65MN/A27
RGC
Regencell Bioscience
0.3507 of 5 stars		$27.87
+5.7%		N/AN/A$13.78BN/AN/A10
BBIO
BridgeBio Pharma
3.4481 of 5 stars		$66.02
+0.1%		$88.19
+33.6%		+107.0%$12.91B$502.08MN/A400
AXSM
Axsome Therapeutics
2.7349 of 5 stars		$227.49
+1.5%		$251.26
+10.5%		+124.0%$11.69B$638.50MN/A380
ARWR
Arrowhead Pharmaceuticals
2.1632 of 5 stars		$79.86
+1.0%		$92.44
+15.8%		+434.5%$11.27B$622.01MN/A400

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
"Golden Dawn": the code name that should be on every investor's radar
Trump's team has officially code-named America's new AI initiative 'Golden Dawn' - a government project involv...
InvestorPlace | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel